en English

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX®

EU flag

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex. Read the PDF document here.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More To Explore

Pathogenesis of Epilepsy
Latest News

4EU Course on Pathogenesis of Epilepsy

The 2022 International 4EU+ Course on Pathogenesis of Epilepsy explores the neurobiology of epilepsy from basic and clinical perspectives. The main objectives of this course